^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) + ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Published date:
07/31/2020
Excerpt:
...patients received concurrent cobimetinib and ipatasertib on days 1-21...Three patients with endometrial or ovarian cancer achieved partial response, all with PTEN-low disease and two with tumor also harboring KRAS mutation.
DOI:
10.1007/s10637-020-00975-6
